Bastion Asset Management Inc. Sells 54,102 Shares of The Cooper Companies, Inc. $COO

Bastion Asset Management Inc. reduced its position in The Cooper Companies, Inc. (NASDAQ:COO) by 43.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 69,395 shares of the medical device company’s stock after selling 54,102 shares during the period. Cooper Companies accounts for approximately 2.7% of Bastion Asset Management Inc.’s portfolio, making the stock its 14th largest holding. Bastion Asset Management Inc.’s holdings in Cooper Companies were worth $4,690,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in COO. Wealth Alliance LLC lifted its stake in shares of Cooper Companies by 4.2% during the 2nd quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock valued at $301,000 after buying an additional 171 shares in the last quarter. Pacer Advisors Inc. grew its stake in Cooper Companies by 0.8% in the 3rd quarter. Pacer Advisors Inc. now owns 23,079 shares of the medical device company’s stock valued at $1,582,000 after buying an additional 182 shares in the last quarter. Citizens Financial Group Inc. RI lifted its position in shares of Cooper Companies by 2.7% during the third quarter. Citizens Financial Group Inc. RI now owns 7,181 shares of the medical device company’s stock worth $492,000 after acquiring an additional 192 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of Cooper Companies by 0.4% during the second quarter. State of Michigan Retirement System now owns 54,344 shares of the medical device company’s stock worth $3,867,000 after acquiring an additional 200 shares in the last quarter. Finally, New York Life Investment Management LLC boosted its holdings in shares of Cooper Companies by 0.7% in the second quarter. New York Life Investment Management LLC now owns 30,019 shares of the medical device company’s stock worth $2,136,000 after acquiring an additional 210 shares during the period. Institutional investors own 24.39% of the company’s stock.

Insider Transactions at Cooper Companies

In other news, insider Holly R. Sheffield acquired 1,230 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were bought at an average cost of $80.75 per share, with a total value of $99,322.50. Following the acquisition, the insider owned 39,052 shares in the company, valued at approximately $3,153,449. This represents a 3.25% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cynthia L. Lucchese purchased 1,784 shares of Cooper Companies stock in a transaction on Monday, December 22nd. The shares were acquired at an average price of $84.06 per share, for a total transaction of $149,963.04. Following the completion of the transaction, the director directly owned 9,445 shares of the company’s stock, valued at approximately $793,946.70. The trade was a 23.29% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 16,014 shares of company stock worth $1,304,416. Company insiders own 1.98% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on COO shares. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Mizuho set a $100.00 price target on shares of Cooper Companies and gave the stock an “outperform” rating in a report on Friday, December 5th. William Blair upgraded shares of Cooper Companies to a “strong-buy” rating in a research report on Friday, January 30th. JPMorgan Chase & Co. upped their target price on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, December 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $94.00 price target (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Cooper Companies has an average rating of “Moderate Buy” and an average price target of $90.77.

Cooper Companies Stock Up 1.6%

COO stock opened at $82.99 on Monday. The company’s 50 day moving average is $81.83 and its 200 day moving average is $74.84. The stock has a market cap of $16.26 billion, a price-to-earnings ratio of 44.14, a price-to-earnings-growth ratio of 2.37 and a beta of 1.03. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $93.00.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Sell-side analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.